查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1876788

数位病理市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Digital Pathology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 199 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球数位病理市场价值为 11 亿美元，预计到 2034 年将以 13.4% 的复合年增长率增长至 38 亿美元。

数位病理市场 - IMG1

数位病理学市场的成长得益于数位化解决方案的日益普及、诊断基础设施的现代化、与电子健康记录 (EHR) 的整合，以及在药物研发和伴随诊断领域应用的不断扩大。数位病理学利用数位影像技术扫描、分析和管理病理切片及相关资料，从而实现远端诊断、人工智慧辅助解读和与 EHR 的无缝整合。组织样本数位化能提高诊断准确性，提升病理学家的工作流程效率，并支援研发工作。该市场涵盖用于获取、储存、检索、共享和分析病理切片资料的硬体和软体解决方案。持续的技术创新，尤其是在肿瘤诊断领域，正在推动市场向前发展，因为製药和研究机构越来越多地利用数位病理学来简化药物研发流程并改善精准医疗方法。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 11亿美元
预测值 38亿美元
复合年增长率 13.4%

由于该产品能够优化工作流程并提高诊断精度，预计到2024年，其市占率将达到51.2%。扫描仪支援远端诊断和远端病理学，减少了实体切片的运输需求。切片管理系统简化了资料处理，改善了跨地域协作，并提高了整体效率。其他产品则可实现日常任务自动化，最大限度地减少人为错误，并加快诊断速度，这在高流量的临床环境中至关重要。

2024年，诊断领域的市场估值达到6.48亿美元。该领域专注于解读数位化组织切片，以在临床工作流程中检测疾病。病理学家依靠数位影像（通常藉助人工智慧分析工具增强）来识别肿瘤、感染或发炎等异常情况，从而取代传统的基于显微镜的工作流程。

2024年，北美数位病理市场占33.4%的份额。美国市场的成长主要得益于药物研发、伴随诊断以及研究机构对更快、更精准的组织分析方法的需求不断增长。联邦政府对生物医学研究和药物开发的投入也进一步推动了数位病理技术在该地区的应用。

全球数位病理市场的主要参与者包括3DHISTECH、Dedalus、CellaVision、丹纳赫公司、罗氏製药、富士胶片控股株式会社、Glencoe Software Inc.、滨松光子学株式会社、Huron Digital Pathology、Ibex Medical Analytics、Indica Labs Inc.、皇家飞利浦公司、Mikroscan Technologies Inc. AI、PathAI、PHC Holding Corporation（Epredia）、Proscia, Inc.、Sectra AB和Visiopharm A/S。这些公司正透过实施多项策略措施来巩固其市场地位。他们投资于先进的高解析度成像设备和人工智慧驱动的分析软体，以提高诊断准确性。许多公司正与医院、研究机构和製药公司建立合作关係，以扩大其在临床和药物开发工作流程中的应用。此外，他们还透过併购来整合技术并拓展产品组合。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
  • 产业影响因素
    • 成长驱动因素
      • 数位化解决方案的采用率不断提高
      • 数位病理诊断基础设施的日益现代化
      • 将数位病理系统与电子健康记录（EHR）集成
      • 在药物发现和伴随诊断的应用日益广泛
    • 产业陷阱与挑战
      • 数位病理学缺乏标准指南
      • 硬体或软体的实施和整合成本很高
    • 市场机会
      • 对远端病理和远端病理解决方案的需求日益增长
  • 成长潜力分析
  • 监管环境
  • 技术进步
    • 当前技术趋势
    • 新兴技术
  • 供应链分析
  • 报销方案
  • 2024年定价分析
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依组件划分，2021-2034年

  • 主要趋势
  • 产品
    • 扫描仪
    • 幻灯片管理系统
    • 其他产品
  • 软体
    • 类型
      • AI增强型影像分析软体
      • 资料管理软体
      • 其他软体
    • 部署模式
      • 基于云端的
      • 现场
  • 服务

第六章：市场估算与预测：依应用领域划分，2021-2034年

  • 主要趋势
  • 诊断
  • 研究
  • 教育和培训

第七章：市场估算与预测：依最终用途划分，2021-2034年

  • 主要趋势
  • 研究机构
  • 实验室
    • 病理实验室
    • 细胞学实验室
  • 其他最终用途

第八章：市场估算与预测：依地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋

第九章：公司简介

  • 3DHISTECH
  • CellaVision
  • Danaher Corporation
  • Dedalus
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • Glencoe Software Inc.
  • Hamamatsu Photonics KK
  • Huron Digital Pathology
  • Ibex Medical Analytics
  • Indica Labs Inc.
  • Koninklijke Philips NV
  • Mikroscan Technologies Inc.
  • Olympus Corporation
  • Paige AI
  • PathAI
  • PHC Holding Corporation
  • Proscia, Inc.
  • Sectra AB
  • Visiopharm A/S
简介目录
Product Code: 7003

The Global Digital Pathology Market was valued at USD 1.1 billion in 2024 and is estimated to grow at a CAGR of 13.4% to reach USD 3.8 billion by 2034.

Digital Pathology Market - IMG1

The growth is fueled by the rising adoption of digital solutions, modernization of diagnostic infrastructure, integration with electronic health records (EHRs), and increasing utilization in drug discovery and companion diagnostics. Digital pathology involves using digital imaging technologies to scan, analyze, and manage pathology slides and related data. It enables remote diagnostics, AI-assisted interpretations, and seamless EHR integration. Digitizing tissue samples enhances diagnostic accuracy, accelerates workflow efficiency for pathologists, and supports research and development. The market encompasses both hardware and software solutions for acquiring, storing, retrieving, sharing, and analyzing pathology slide data. Continuous technological innovations, particularly in oncology diagnostics, are driving the market forward, as pharmaceutical and research institutions increasingly leverage digital pathology to streamline drug development and improve precision medicine approaches.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.1 Billion
Forecast Value$3.8 Billion
CAGR13.4%

The product segment held a 51.2% share in 2024 owing to its ability to optimize workflow and enhance diagnostic precision. Scanners enable remote diagnostics and telepathology, reducing the need to transport physical slides. Slide management systems simplify data handling, improve collaboration across locations, and increase overall efficiency. Other product offerings automate routine tasks, minimize human error, and accelerate diagnosis, which is crucial in high-volume clinical environments.

The diagnostics segment was valued at USD 648 million in 2024. This segment focuses on interpreting digitized tissue slides for disease detection within clinical workflows. Pathologists rely on digital images, often enhanced with AI-based analysis tools, to identify abnormalities such as tumors, infections, or inflammatory conditions, replacing traditional microscope-based workflows.

North America Digital Pathology Market held a 33.4% share in 2024. Growth in the U.S. is driven by increased adoption in drug discovery, companion diagnostics, and research institutions seeking faster, more accurate tissue analysis methods. Federal investment in biomedical research and drug development further supports the expansion of digital pathology technologies across the region.

Key players in the Global Digital Pathology Market include 3DHISTECH, Dedalus, CellaVision, Danaher Corporation, F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corporation, Glencoe Software Inc., Hamamatsu Photonics K.K., Huron Digital Pathology, Ibex Medical Analytics, Indica Labs Inc., Koninklijke Philips N.V., Mikroscan Technologies Inc., Olympus Corporation (Evident Scientific, Inc.), Paige AI, PathAI, PHC Holding Corporation (Epredia), Proscia, Inc., Sectra AB, and Visiopharm A/S. Companies in the Global Digital Pathology Market are strengthening their foothold by implementing several strategic initiatives. They are investing in advanced, high-resolution imaging devices and AI-powered analysis software to improve diagnostic accuracy. Many are forming partnerships with hospitals, research institutions, and pharmaceutical firms to expand adoption in clinical and drug development workflows. Mergers and acquisitions are being used to consolidate technologies and broaden product portfolios.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Component trends
    • 2.2.3 Application trend
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing adoption of digital solutions
      • 3.2.1.2 Growing modernization in diagnostic infrastructure in digital pathology
      • 3.2.1.3 Integration of digital pathology systems with electronic health records (EHRs)
      • 3.2.1.4 Increasing application in drug discovery and companion diagnostics
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Lack of standard guidelines for digital pathology
      • 3.2.2.2 High cost associated with the implementation and integration of hardware or software
    • 3.2.3 Market opportunities
      • 3.2.3.1 Growing demand for remote pathology and telepathology solutions
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Supply chain analysis
  • 3.7 Reimbursement scenario
  • 3.8 Pricing analysis, 2024
  • 3.9 Future market trends
  • 3.10 Gap analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Product
    • 5.2.1 Scanners
    • 5.2.2 Slide management systems
    • 5.2.3 Other products
  • 5.3 Software
    • 5.3.1 Type
      • 5.3.1.1 AI enhanced image analysis software
      • 5.3.1.2 Data management software
      • 5.3.1.3 Other software
    • 5.3.2 Deployment mode
      • 5.3.2.1 Cloud-based
      • 5.3.2.2 On-premises
  • 5.4 Services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Diagnostics
  • 6.3 Research
  • 6.4 Education and training

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Research institutes
  • 7.3 Laboratories
    • 7.3.1 Pathology labs
    • 7.3.2 Cytology labs
  • 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 India
    • 8.4.3 Japan
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 3DHISTECH
  • 9.2 CellaVision
  • 9.3 Danaher Corporation
  • 9.4 Dedalus
  • 9.5 F. Hoffmann-La Roche Ltd
  • 9.6 Fujifilm Holdings Corporation
  • 9.7 Glencoe Software Inc.
  • 9.8 Hamamatsu Photonics K.K.
  • 9.9 Huron Digital Pathology
  • 9.10 Ibex Medical Analytics
  • 9.11 Indica Labs Inc.
  • 9.12 Koninklijke Philips N.V.
  • 9.13 Mikroscan Technologies Inc.
  • 9.14 Olympus Corporation
  • 9.15 Paige AI
  • 9.16 PathAI
  • 9.17 PHC Holding Corporation
  • 9.18 Proscia, Inc.
  • 9.19 Sectra AB
  • 9.20 Visiopharm A/S